Last reviewed · How we verify
Ag-D-CIK
Ag-D-CIK is a monoclonal antibody that targets CD47.
Ag-D-CIK is a monoclonal antibody that targets CD47. Used for Treatment of relapsed or refractory acute myeloid leukemia.
At a glance
| Generic name | Ag-D-CIK |
|---|---|
| Sponsor | Shenzhen Hornetcorn Bio-technology Company, LTD |
| Drug class | CD47 antibody |
| Target | CD47 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CD47 is a protein that is overexpressed on the surface of cancer cells and is involved in immune evasion. By targeting CD47, Ag-D-CIK aims to enhance the body's immune response against cancer cells.
Approved indications
- Treatment of relapsed or refractory acute myeloid leukemia
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ag-D-CIK CI brief — competitive landscape report
- Ag-D-CIK updates RSS · CI watch RSS
- Shenzhen Hornetcorn Bio-technology Company, LTD portfolio CI